As the use of plasma cfDNA analysis in the clinical setting continues to grow, extra caution should be taken to accurately determine the origin of the mutations and differentiate tumor-derived ctDNA from the biological confounding factors present in the blood, such as CH mutations. Here, C4B is linked to neoplasm.